Patents Issued in April 6, 2021
  • Patent number: 10966995
    Abstract: The invention provides compositions and methods for radioprotection and chemoprevention using therapeutic and prophylactics methods of using (S,S)-SDG (R,R)-SDG, (S,R)-SDG (R,S)-SDG, SDG, SECO, EL, ED, analogs thereof, stereoisomers thereof and other related molecules.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: April 6, 2021
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventor: Melpo Christofidou-Solomidou
  • Patent number: 10966996
    Abstract: Disclosed is a Glechoma longituba (Nakai) Kupr. extract, specifically compounds I and II, a preparation method for same, and a use thereof in preparing a medicament for blood glucose decease, blood lipids decrease, weight loss, and kidney disease treatment or a method for treatment of said diseases, and a composition containing the extract.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: April 6, 2021
    Assignees: SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES, NANJING PAILEXING PHARMACEUTICAL TECHNOLOGY LTD.
    Inventors: Weiliang Zhu, Heyao Wang, Yong Zhang, Peng Sun, Bo Li, Zhijian Xu, Hualiang Jiang, Kaixian Chen
  • Patent number: 10966997
    Abstract: The present invention in various aspects and embodiments provides methods for the treatment or prevention of degenerative disc disease or chronic lower back pain.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: April 6, 2021
    Assignee: ECM DIAGNOSTICS, INC.
    Inventors: Ondrej Slaby, Manu Capoor
  • Patent number: 10966998
    Abstract: Cancer therapies that combine epigenetic modulating agent(s) with immune modulating agent(s), which were remarkably identified to provide an improved treatment regimen over single agent therapy, are disclosed. In particular embodiments, the invention provides for improved treatment of NSCLC in patients via administration of exemplary immune modulating agents anti-PD-1 antibody or anti-PD-L1 antibody, which were observed to show enhanced activity in combination with the exemplary epigenetic modulating agent 5-deoxyazacytidine. Further, expression markers of responsive neoplastic cells are also disclosed.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: April 6, 2021
    Assignee: The Johns Hopkins University
    Inventors: Stephen B. Baylin, Drew M. Pardoll, Suzanne L. Topalian
  • Patent number: 10966999
    Abstract: Provided herein are the 3?3? cyclic phosphonate dinucleotides of general formula J, their pharmaceutically acceptable salts, a pharmaceutical composition containing them and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: April 6, 2021
    Assignee: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I.
    Inventors: Gabriel Birkus, Ondrej Pav, Tomas Jandusik, Ivan Rosenberg, Radim Nencka
  • Patent number: 10967000
    Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising amino acid sequence of SEQ ID NO:1, a fragment of any one sequence of SEQ ID NO:1, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: April 6, 2021
    Assignee: Gemvax & Kael Co., Ltd.
    Inventor: Sang Jae Kim
  • Patent number: 10967001
    Abstract: The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: April 6, 2021
    Assignee: CYTOSORBENTS CORPORATION
    Inventors: Phillip P. Chan, Wei-Tai Young, Vincent J. Capponi, Thomas D. Golobish, Humayra Begum Ali
  • Patent number: 10967002
    Abstract: A premix is disclosed. The premix includes a nitrate compound and salts thereof in the amount of greater than about 50% by weight of the premix. The premix also includes vitamins and trace minerals. The premix is formulated for use in at least one of a gestation or lactation phase of an animal and in an amount of less than about five percent by weight (5.0 wt %) inclusion per metric ton of the premix. A supplement for an animal feed for feeding during at least one of an animal's gestation phase and/or lactation phase is also disclosed. A method for feeding an animal is also disclosed.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: April 6, 2021
    Assignee: CAN TECHNOLOGIES, INC.
    Inventors: Moniek Van Den Bosch, Ad Van Wesel
  • Patent number: 10967003
    Abstract: Provided are multiply functional telodendrimers. The telodendrimers can be used for combination drug delivery. The telodendrimers may have one or more crosslinking groups (e.g., reversible photocrosslinking groups). The telodendrimers can aggregate to form nanocarriers. Cargo such as combinations of drugs, imaging probes, and other materials may be sequestered in the core of the aggregates via non-covalent or covalent interactions with the telodendrimers. Such nanocarriers may be used in drug delivery applications and imaging applications.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: April 6, 2021
    Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Juntao Luo, Changying Shi, Dandan Guo
  • Patent number: 10967004
    Abstract: Compositions and methods of mineral pitch resin as a semisolid, solid, and powder comprising a higher than negligible content of at least one of gold, silver and platinum are provided. For example, the product could have a content of above 1 ppm of one or more precious metals. Such mineral pitch resin compositions may be safely consumed orally or topically. Compositions and methods of mineral pitch resin comprising at least one of gold, silver and platinum added during processing to result in a product having a content of above 0.01 ppm of a precious metal is also provided.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: April 6, 2021
    Inventor: Nodari Rizun
  • Patent number: 10967005
    Abstract: Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: April 6, 2021
    Assignee: CELGENE CORPORATION
    Inventors: Stewart Abbot, Tianjian Li, Bitao Liang
  • Patent number: 10967006
    Abstract: The present invention provides a method for treating wounds by applying cells as described in this application. In one aspect the method provides treatment for cutaneous wounds. In general embodiments the cells are delivered to the wound without being attached to a functionalized substrate in the delivery vehicle.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: April 6, 2021
    Assignees: ABT Holding Company, Katholieke Universiteit Leuven
    Inventors: Aernout Luttun, Robert J Deans
  • Patent number: 10967007
    Abstract: Embodiments of the disclosure concern compositions and methods of use related to particular c-kit+ mesenchymal cells, including cardiac stem cells, obtained from a pediatric or neonatal individual. In specific embodiments, the cells, or conditioned medium or partial or total secretomes thereof, are provided in an effective amount to an individual in need thereof.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: April 6, 2021
    Assignee: University of Maryland, Baltimore
    Inventor: Sunjay Kaushal
  • Patent number: 10967008
    Abstract: The present invention relates to methods for the preparation of compositions comprising adipose tissue-derived secretions, for example those derived from bovine adipose tissue, and the use of such compositions in the preparation of a pharmaceutical composition for topical use. The invention also relates to the use of adipose tissue-derived secretions and pharmaceutical compositions thereof for the topical treatment of a non-inflammatory condition, for example the treatment of a skin condition, and for the stimulation of hair growth in a subject by topical application. The invention also relates to the use of adipose tissue-derived secretions and pharmaceutical compositions thereof for the topical treatment of acne.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: April 6, 2021
    Assignee: Cell Ideas Pty Ltd
    Inventors: Graham Vesey, Rebecca Anne Webster
  • Patent number: 10967009
    Abstract: The present invention provides compositions and methods for wound healing and tissue regeneration. The compositions of the present invention comprise amniotic membrane of the placenta. In certain embodiments, the composition comprises amniotic membrane powder or solubilized amniotic membrane (SAM). In some aspects, the composition is cell-free and rich in cytokines, extracellular matrix proteins, and other components that improve tissue regeneration. In one aspect, the composition is a hydrogel scaffold that comprises amniotic membrane. The present invention reduces contraction and improves blood vessel development in regenerating tissue.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: April 6, 2021
    Assignee: Wake Forest University Health Sciences
    Inventors: Sean V. Murphy, Aleksander Skardal, Anthony Atala
  • Patent number: 10967010
    Abstract: The invention provides compositions comprising one or more bacterial strains for use in a method of reducing the level of Enterobacteriaceae in the gastrointestinal tract.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: April 6, 2021
    Assignee: 4D Pharma PLC
    Inventors: Laureen Crouzet, Chloe Habouzit, Annick Bernalier-Donadille
  • Patent number: 10967011
    Abstract: Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: April 6, 2021
    Assignee: Seres Therapeutics, Inc.
    Inventors: Gregory McKenzie, Mary-Jane Lombardo McKenzie, David N. Cook, Marin Vulic, Geoffrey von Maltzahn, Brian Goodman, John Grant Aunins, Matthew R. Henn, David Arthur Berry, Jonathan Winkler
  • Patent number: 10967012
    Abstract: Methods of formulating live biotherapeutics are disclosed in which a deficiency or excess of a specific bacterial strain in a person's microbiome is identified by comparing a gene-specific characterization of the person's microbiome against a comprehensive, non-redundant reference gene catalog, and the biotherapeutic is formulated by selecting bacteria to address the deficiency or excess. Embodiments include the formulation of live biotherapeutics for improving the health of a person's vaginal microbiome, i.e. using a vaginal reference gene catalog, and may be suitable for ameliorating, treating, or preventing a malignancy such as a cancer of the female genitourinary system.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: April 6, 2021
    Assignee: University of Maryland, Baltimore
    Inventors: Jacques Ravel, Michael France, Lindsay Rutt, Bing Ma
  • Patent number: 10967013
    Abstract: The present invention provides an isolated lactic acid bacterium, Lactobacillus plantarum subsp. plantarum PS128 deposited under DSMZ Accession No. DSM 28632, for prophylaxis or treatment of a stress-induced disorder. The present invention further provides a composition for prophylaxis or treatment of a stress-induced disorder that comprises Lactobacillus plantarum subsp. plantarum PS128. Moreover, the present invention provides a method for prophylaxis or treatment of a stress-induced disorder in a subject that comprises a step of administering an effective amount of Lactobacillus plantarum subsp. plantarum PS128 to the subject.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: April 6, 2021
    Assignee: National Yang-Ming University
    Inventors: Ying-Chieh Tsai, Wei-Hsien Liu, Yi-Chen Juan, Chien-Chen Wu
  • Patent number: 10967014
    Abstract: The invention relates to pneumoviral virions comprising a viral genome that has a mutation in a gene coding for a protein that is essential for infectivity of the pneumovirus, whereby the mutation causes a virus produced from only the viral genome to lack infectivity, and whereby the virion comprises the protein in a form and in an amount that is required for infectivity of the virion. The invention also relates to methods for producing the pneumoviral virions and for using the virions in the treatment or prevention of pneumoviral infection and disease. A preferred pneumoviral virion is a virion of Respiratory Syncytial Virus in which preferably the gene for the G attachment protein is inactivated and complemented in trans.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: April 6, 2021
    Assignee: De Staat der Nederlanden, vert. door de minister van VWS
    Inventors: Willem Luytjes, Myra Noorely Widjojoatmodjo
  • Patent number: 10967015
    Abstract: A method for treating a tumor by administering to a subject in need of such treatment an effective amount for treating the tumor of a Poxviridae decapping deficient mutant virus. Also disclosed are mutant Poxviridae and pharmaceutical formulations for use in the method.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: April 6, 2021
    Assignee: New York University
    Inventor: Ian J Mohr
  • Patent number: 10967016
    Abstract: The present disclosure relates to the field of drugs and health foods. Disclosed is a traditional Chinese medicine composition comprising GANODERMA polysaccharide, MORINDAE OFFICINALIS RADIX polysaccharide, POLYGONATI RHIZOMA polysaccharide, ANGELICAE SINENSIS RADIX oil and MYRISTICAE SEMEN oil. Experiments show that the traditional Chinese medicine composition has a scientific formulation, synergistic functions, without toxic and side effects, and not only has nutritional value but also inhibits the growth of tumor. Comparing with individual components, the composition significantly increases the percentages of CD4+ and CD8+ cells in lymphocytes of the tumor stroma, enhances body immune function, restores normal immune surveillance function, decreases VEGF and TGF-?1 positive cells in tumor tissue, assists in treating tumor, increases antitumor effects of chemotherapy drugs, improves immune status of body, has the function of restoring normal immune surveillance, preventing and assisting in treating tumor.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: April 6, 2021
    Assignee: INFINITUS (CHINA) COMPANY LTD.
    Inventors: Yuanyuan Wang, Fangli Ma, Renhuai Cong, Minghua Hu, Chung Wah Ma
  • Patent number: 10967017
    Abstract: The present disclosure relates to the field of drugs and health foods. Disclosed is a traditional Chinese medicine composition comprising GANODERMA polysaccharide, GRIFOLA FRONDOSA polysaccharide, ANGELICAE SINENSIS RADIX oil and CINNAMOMI CORTEX oil. Experiments show that the traditional Chinese medicine composition has a scientific formulation, synergistic functions, without toxic and side effects, and not only has nutritional value but also inhibits the growth of tumor. Comparing with individual components, the composition significantly increases the percentages of CD4+ and CD8+ cells in lymphocytes of the tumor stroma, increases body immune function, recovers normal immune surveillance function, decreases the expression rate of VEGF and TGF-? 1 positive cells in tumor tissue, assists in treating tumor, increases antitumor effects of chemotherapy drugs, improves immune status of body, has the function of restoring normal immune surveillance, preventing and assisting in treating tumor.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: April 6, 2021
    Assignee: INFINITUS (CHINA) COMPANY LTD.
    Inventors: Minghua Hu, Fangli Ma, Yuanyuan Wang, Chung Wah Ma, Renhuai Cong, Lingyun Xiao
  • Patent number: 10967018
    Abstract: A method for the extraction and isolation of the terpene and isoprenoid compounds from plant material, followed by a centrifugal force induced selective crystallization of isoprenoids resulting in a separation of terpene and isoprenoid fractions. This this method is suitable for the extraction of cannabinoids from Cannabis and the enrichment tetrahydrocannabinolic acid and reduction of tetrahydrocannabinol in an extract.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: April 6, 2021
    Assignee: Concentrated Consulting Group, LLC
    Inventor: Bradley Lee Robertson
  • Patent number: 10967019
    Abstract: A use of an emblica extract in preparing a pharmaceutical composition for protecting mitochondria in retina is provided. When the pharmaceutical composition, which comprises the emblica extract, is provided to retinal cells, a use of the pharmaceutical composition comprises improvement of the ability of performing the oxidative phosphorylation for the synthesis of the adenosine triphosphate (ATP) by the mitochondria in the retinal cells under or exposed to ultraviolet light, and improvement of the coupling efficiency of the synthesis of the adenosine triphosphate by the mitochondria.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: April 6, 2021
    Assignee: TAIWAN MITOCHONDRION APPLIED TECHNOLOGY CO., LTD.
    Inventors: Han-Chung Cheng, Chi-Tang Tu, Shun-Chieh Yang, Man-Ching Shen
  • Patent number: 10967020
    Abstract: The custard apple peel nanoparticles may be manufactured by extracting custard apple peels in a solvent, spraying the custard apple peel extracts into boiling water under ultrasonic conditions to produce a first mixture, sonicating the mixture, stirring the mixture, and drying the mixture to obtain custard apple peel nanoparticles. In an embodiment, the custard apple peel may be peel of Annona reticulata. In an embodiment, the custard apple peel nanoparticles may have improved antibacterial or antioxidant properties.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: April 6, 2021
    Assignee: King Saud University
    Inventors: Hany M. Yehia, Hatem Salama Ali, Ebtesam Mohammed Al Olayan, Manal Fawzy Elkhadragy, Mohamed Fekry Mansour Serag Eldin, Manal Ahmed Awad
  • Patent number: 10967021
    Abstract: The present invention provides a new use or method of use of a thylakoid extract, for oral route of administration, and a composition comprising the thylakoid extract in adjunction with an acceptable carrier for oral administration. Besides the pharmaceutical use, the thylakoid extract enters the composition of food or food supplements, or medication for its innocuity and its capacity to provide a diet enriched in anti-oxidants and anti-inflammatory compounds. Therefore, in accordance with the present invention is provided the use of athylakoid extract in the making of an oral composition for treating preventing a disease or disorder involving the formation of reactive oxygen species or inflammation. Also is provided a method for treating or preventing a disease or disorder involving the formation of reactive oxygen species inflammation in an individual, which comprises the step of orality administering an effective dose of a thylakoid extact.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: April 6, 2021
    Assignee: GROUPE SANTÉ DEVONIAN
    Inventors: Marc Purcell, Réjean Drouin
  • Patent number: 10967022
    Abstract: A botanical extract for use in skin care, wherein the botanical extract is at least an extract from the testa of the seed of Anacardium occidentale L.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: April 6, 2021
    Assignee: Innophos, Inc.
    Inventors: Jatinder Rana, Kylie Mitchell
  • Patent number: 10967023
    Abstract: Disclosed is a Chinese medicinal composition prepared from the following medical raw materials in parts by weight: 1 part of ginseng, 0.8-1.5 parts of ginkgo leaf and 0.018-0.030 part of stigma croci.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: April 6, 2021
    Assignee: Shineway Pharmaceutical Group Ltd.
    Inventors: Jianxun Liu, Vivian Zhang, Zhigang Li, Shyflysky Zhang, Xiuwei Guan, Iris Lu, Weibo Gao, Li Xu, Wenting Song
  • Patent number: 10967024
    Abstract: A synergistic herbal stimulant composition comprises a mixture, in powdered or extract form, of two or more herbal stimulant ingredients and at least one catalytic herbal ingredient, which effects a synergy between the herbal stimulant ingredients. The herbal stimulant ingredients are preferably selected from the group consisting of Horny Goat Weed (Epimedium Sagittatum), Rhodiola Root (Rhodiola Rosea), Elueuthero Root (Eleutherococcus), Nettle Leaf (Urticaria Dioica), Ashwagandha Root (Withania Somnifera), Maca Root (Lepidium Meyenii), Moringa Root (Moringa Oleifera), and Cowitch (Macuna Pruriens). The catalytic herbal ingredient is preferably Moses-in-a-basket (Tradescantia Spathacea).
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: April 6, 2021
    Inventor: Aretha Duncan
  • Patent number: 10967025
    Abstract: The main objective of the present invention is to develop an herbal formulation with high polyphenol concentrations. A therapeutic effect of ingredients in herbal composition with Antioxidants, Anti-inflammatories, Anti Viral & Anti Microbial properties to reduce Oxidative Stress, Inflammation, Viral and Microbial Infections. The herbal composition promotes management of diabetes, regulation of cholesterol, also immune system processes that helps to fight against viral and bacterial infections, colds, or the flu, skin ailments such as Psoriasis & eczema. Herbal Composition comprises synergistic combination of Moringa Oleifera Leaf Powder, Spirulina & Aqueous extracts of Oregano Vulgare Leaf Extract, Shilajit extract, Rosemary Leaf extract, Pomegranate Fruit Preel extract, Amla fruit extract, Fenugreek Seed Extract, Curcumin Extract, Piperine extract. Therefore, the chosen herbal blend provides the body with all of the vitamins, minerals, and nutrients it needs to continuously boost health.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: April 6, 2021
    Assignee: Moringo Organics Inc.
    Inventor: Karen Vieira
  • Patent number: 10967026
    Abstract: The present application is directed to composition comprising various maca extracts and the use of such compositions for treating certain diseases, disorders, and conditions.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: April 6, 2021
    Assignee: JDS Therapeutics, LLC
    Inventors: James R. Komorowski, Sara Perez Ojalvo
  • Patent number: 10967027
    Abstract: The invention provides a method for extracting active therapeutic components from plant materials of the cyclanthera pedata plant which comprises immersing said plant material containing active components and selected from the group consisting of fruits, flowers, leaves, stems, twigs, bark, wood, buds, seeds, roots, and pods in a solvent for a period of time of about 30 minutes to about 10 hours to achieve transfer of active components from the plant material to the solvent, separating the solvent containing active components from the plant material, and evaporating or distilling the solvent to produce a concentrated fraction containing active components. The invention further includes compositions and therapeutic formulations of such extracts to treat hypercholesterolemia and other high lipid related diseases.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: April 6, 2021
    Assignee: PROCAPS S.A.
    Inventors: Alejandro Mario Díaz Rebolledo, Carlos Perez Rebolledo
  • Patent number: 10967028
    Abstract: Disclosed is a novel use of a composition comprising as an active ingredient an Artemisia umbelliformis extract. A composition according to the present description shows hair follicle cell proliferation or hair growth effect by means of comprising an Artemisia umbelliformis extract. Therefore, due to said effect, the Artemisia umbelliformis extract has hair loss prevention or hair growth stimulation effect.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: April 6, 2021
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Pil Joon Park, Seung Hyun Shin, Hae Kwang Lee, Jon Hwan Lee, Tae Ryong Lee, Eun Gyung Cho
  • Patent number: 10967029
    Abstract: This invention provides a method of using extract of Cistanche tubulosa. The extract was used to prevent, slow down, or treat an eye disease caused by oxidative stress. The method includes administrating to a subject in need a therapeutically effective amount of the extract of Cistanche tubulosa to prevent, slow down, or treat an eye disease caused by oxidative stress.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: April 6, 2021
    Assignee: Sinphar Pharmaceutical Co., Ltd.
    Inventor: Chih-Wen Lee
  • Patent number: 10967030
    Abstract: The invention relates to the field of traditional Chinese medicine, in particular to provides traditional Chinese medicine compositions for the treatment of psoriasis, their preparations and their preparation methods. The Chinese medicine compositions of the invention are consisted of 20-80 parts of Rumex madaio, 20-80 parts of Radix sophora flavescens, 10-50 parts of Herba Siphonostegiae, 10-40 parts of Chinese pulsatilla chinensis, and 5-30 parts of Acacia catechu, by weight. The invention also includes the preparation methods of the traditional Chinese medicine compositions and the preparations containing the traditional Chinese medicine compositions and method for preparing the same.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: April 6, 2021
    Assignee: Beijing Zhendong Guangming Pharmaceutical Research Institute Co., Ltd.
    Inventors: Siju Zhang, Jinhua Wang, Wenjie Qin, Xiaoning Yang, Juanjuan Liang, Hongjiang Hao, Hongyu Wang
  • Patent number: 10967031
    Abstract: Disclosed is a method of treating and/or preventing atopic dermatitis (AD) in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a composition comprising a Sanguisorba officinalis root extract, an Ailanthus altissima bark extract, a Rheum palmatum root extract, a Cnidium monnieri fruit extract, a Scutellaria baicalensis root extract, and Glycyrrhiza glabra root extract thereby treating and/or preventing AD in the subject.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: April 6, 2021
    Assignee: KAMEDIS LTD.
    Inventors: Sharon Rozenblat, Yonit Bomstein, Jonathan Marder
  • Patent number: 10967032
    Abstract: The present invention relates to a hypertension treatment. More particularly, the present invention relates to combination of four herbs' extract including 95% ethanolic extract of U. rhynchophylla (UR95), 95% ethanolic extract of P. thomsonii (PT95), 95% ethanolic extract of P. notoginseng (PN95), and 50% ethanolic extract of A. orientale (AO50) in particular range of ratio (known as F1 ratio), and all the raw herbs were then extracted in total by using 50% ethanol (known as F1-2) for use in a medicament for treating hypertension and hypertension-related complications and a composition thereof.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: April 6, 2021
    Inventor: Mun Fei Yam
  • Patent number: 10967033
    Abstract: Disclosed are compositions containing: a) Phaseolus vulgaris extract; b) Cynara scolymus extract; c) Echinacea angustifolia extract; d) Vitis vinifera extract and optionally e) Panax ginseng extract, mixed with suitable excipients.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: April 6, 2021
    Assignee: Indena S.P.A.
    Inventors: Ezio Bombardelli, Fabrizio Corti
  • Patent number: 10967034
    Abstract: A method for decolorizing a muscadine pomace grape extract by processing the clarified extract by ultrafiltration through a 500-5000 kDa microfiltration membrane to obtain a first permeate in which flavor components are removed. The retentate is subjected to ultrafiltration through a 25-100 kDa ultrafiltration membrane to obtain a second permeate and a second retentate. The polymeric condensed tannins are removed in the second retentate and the second permeate is the decolorized extract having increased levels of polyphenols and lowered levels of sugars and condensed tannins compared to the first retentate. The decolorized extract can be incorporated into skin care compositions, which can also include beta-glucan and grape seed extract. The skin care compositions can and applied to the skin to maintain healthy skin without discoloration, protecting against ultraviolet radiation, and inhibiting the production of anti-inflammatory mediators in skin cells.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: April 6, 2021
    Assignee: Shaklee Corporation
    Inventors: Teodoro Ianiro, Sonhee C. Park, Ron Flores, Christos Kyrou, Laurel A. Fisher
  • Patent number: 10967035
    Abstract: A feed additive suitable for use in commercial aquaculture, made from whole dried seaweed powder supplemented with 2.5 percent (w/w) andrographolide, increases feed conversion ratio (the ratio of weight gain to weight of feed used) and growth rate, while reducing vulnerability to water-borne marine pathogens such as Piscirickettsia salmonis and white-spot syndrome virus.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: April 6, 2021
    Assignee: HP Ingredients Corp.
    Inventors: Annie Eng, Juan O. Hancke
  • Patent number: 10967036
    Abstract: The present invention relates to a composition comprising a first onion extract (A), and liposomes, wherein at least a portion of the onion extract is encapsulated in the liposomes. Furthermore the present invention relates to a method for preparing a composition comprising a first onion extract (A), and liposomes, wherein at least a portion of the onion extract is encapsulated in the liposomes. Further, the present invention relates to a composition comprising an onion extract (A) (Allium cepa) and liposomes, obtainable by or obtained by the method. Furthermore, the present invention relates to compositions comprising a first onion extract (A), and liposomes, wherein at least a portion of the onion extract is encapsulated in the liposomes, for use in treating and/or preventing scars.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: April 6, 2021
    Assignee: HRA Pharma
    Inventors: Peter Boderke, Martina Heberer, Petra Scheppler
  • Patent number: 10967037
    Abstract: The present invention discloses a process for modifying the natural composition of tocotrienol-rich fraction to achieve a product with reduced ?-tocopherol content, enhanced ?- and ?-tocotrienol content and also with an enriched total tocotrienol concentration.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: April 6, 2021
    Assignee: PALM NUTRACEUTICALS SDN. BHD.
    Inventor: Ping Tou Gee
  • Patent number: 10967038
    Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor (poly-)peptides, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of non-chronic or chronic inflammatory eye diseases, such as inflammatory diseases of the blephara, conjunctiva, cornea, sclera, the vitreous body, uvea, ciliary body, choroid, orbital bone, lacrimal gland, or iris, in particular wherein the inflammatory disease is selected from hordeolum, chalazion, conjunktivitis, keratitis, scieritis, episcleritis, endophthalmitis, panophtalmitis, irititis, uveitis, cyclitis, chorioiditis, orbital phlegmon, and myositis of the eye muscle etc.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: April 6, 2021
    Assignee: Xigen Inflammation Ltd.
    Inventors: Jean-Marc Combette, Catherine Deloche, Claire Abadie
  • Patent number: 10967039
    Abstract: A process for the preparation of targeting nanoparticles of a poly(alkyl cyanoacrylate) homopolymer or copolymer, wherein said method comprises, in a single step, the anionic polymerisation of an oil-in-water miniemulsion as herein defined. The invention also relates to nanoparticles produced from said process and to their use in medicine.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: April 6, 2021
    Assignee: SINTEF TTO AS
    Inventors: Ruth Schmid, Per Stenstad, Yrr Morch, Heidi Johnsen
  • Patent number: 10967040
    Abstract: The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: April 6, 2021
    Assignee: Levo Therapeutics, Inc.
    Inventors: Mark C. Manning, Ryan E. Holcomb, Derrick S. Katayama, Christopher Bryant, Sara Cotter, Joseph William Cormier
  • Patent number: 10967041
    Abstract: The invention provides a combination treatment for ischemia conditions in or otherwise affecting the CNS, such as stroke. The treatment involves administration of a PSD-95 inhibitor and performing reperfusion therapy (e.g., by administration of tPA). Administering a PSD-95 inhibitor in combination with reperfusion therapy increases the efficacy of the reperfusion therapy and/or slows the decline in efficacy of reperfusion therapy with time after onset of ischemia thus extending the window in which reperfusion therapy can be administered.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: April 6, 2021
    Assignee: NoNO Inc.
    Inventor: Michael Tymianski
  • Patent number: 10967042
    Abstract: Provided herein are peptidomimetic macrocycles containing amino acid sequences with at least two modified amino acids that form an intramolecular cross-link that can help to stabilize a secondary structure of the amino acid sequence. Suitable sequences for stabilization include those with homology to the p53 protein. These sequences can bind to the MDM2 and/or MDMX proteins. Also provided herein are methods of using such macrocycles for the treatment of diseases and disorders, such as cancers or other disorders characterized by a low level or low activity of a p53 protein or high level of activity of a MDM2 and/or MDMX protein.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: April 6, 2021
    Assignee: AILERON THERAPEUTICS, INC.
    Inventors: Vincent Guerlavais, Carl Elkin, Huw M. Nash, Tomi K. Sawyer, Bradford J. Graves, Eric Feyfant
  • Patent number: 10967043
    Abstract: This invention provides a method of colonic cleansing.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: April 6, 2021
    Assignee: Bausch Health Ireland Limited
    Inventors: Dennis Riff, Gary S. Jacob, Kunwar Shailubhai, Patrick H. Griffin
  • Patent number: 10967044
    Abstract: The present invention relates to lipopeptide-based compounds for use in the diagnosis, prevention and/or treatment of a liver disease or condition, preferably liver involved metabolic diseases, as well as in the control or modification of the cholesterol level or cholesterol uptake and, thus, diagnosis, prevention and/or treatment of a cardiovascular disease. The present invention furthermore relates to an in vitro or in vivo assay or method for testing or measuring the NTCP-mediated transport of test compound(s). The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a liver disease or condition, comprising administering a therapeutically effective amount of a lipopeptide-based compound to a patient. The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a cardiovascular disease.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: April 6, 2021
    Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Volker Cleeves, Stephan Urban, Ralf Kubitz